American Heart Journal
Volume 157, Issue 6 , Pages 1026-1034 , June 2009

Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: Analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database

  • Kiran K. Khush, MD

      Affiliations

    • Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA
    • ,
  • Gudaye Tasissa, PhD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Javed Butler, MD, MPH

      Affiliations

    • Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA
    • ,
  • Dana McGlothlin, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of California, San Francisco, CA
    • ,
  • Teresa De Marco, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, University of California, San Francisco, CA
    • Corresponding Author InformationReprint requests: Teresa De Marco, MD, Division of Cardiology, Department of Medicine, University of California, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143-0124.
    • ,
  • for the ESCAPE Investigators

Received 6 November 2008 ,Accepted 13 February 2009.

References 

  1. Enriquez-Sarano M, Rossi A, Seward JB, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153–159
  2. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105:1663–1668
  3. Cogolludo A, Moreno L, Villamor E. Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. Pharmacology. 2007;79:65–75
  4. Blitzer ML, Loh E, Roddy MA, et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol. 1996;28:591–596
  5. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102:1718–1723
  6. Abramson SV, Burke JF, Kelly JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888–895
  7. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J. 1992;124:1035–1045
  8. Saxon LA, Stevenson WG, Middlekauff HR, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;72:62–65
  9. Moller JE, Hillis GS, Oh JK, et al. Prognostic importance of secondary pulmonary hypertension after acute myocardial infarction. Am J Cardiol. 2005;96:199–203
  10. Binanay C, Califf RM, Hasselblad V, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE trial. Jama. 2005;294:1625–1633
  11. Shah MR, O'Connor CM, Sopko G, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J. 2001;141:528–535
  12. Chatterjee K, De Marco T, Alpert JS. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med. 2002;162:1925–1933
  13. Budev MM, Arroliga AC, Jennings CA. Diagnosis and evaluation of pulmonary hypertension. Cleve Clin J Med. 2003;70(Suppl 1):S9–S17
  14. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124:1017–1025
  15. Capomolla S, Febo O, Guazzotti G, et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant. 2000;19:426–438
  16. de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol. 1998;32:948–954
  17. Di Salvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143–1153
  18. Gavazzi A, Berzuini C, Campana C, et al. Value of right ventricular ejection fraction in predicting short-term prognosis of patients with severe chronic heart failure. J Heart Lung Transplant. 1997;16:774–785
  19. Juilliere Y, Barbier G, Feldmann L, et al. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J. 1997;18:276–280
  20. La Vecchia L, Bedogni F, Castellani A, et al. Assessment of right ventricular function and interstitial fibrosis in idiopathic dilated cardiomyopathy: hemodynamic correlates and prognostic value. G Ital Cardiol. 1998;28:513–523
  21. La Vecchia L, Varotto L, Zanolla L, et al. Right ventricular function predicts transplant-free survival in idiopathic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown). 2006;7:706–710
  22. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:202–208
  23. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865–870
  24. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol. 2004;43:764–770

 Hector O. Ventura, MD served as guest editor on this manuscript.

PII: S0002-8703(09)00162-8

doi: 10.1016/j.ahj.2009.02.022

American Heart Journal
Volume 157, Issue 6 , Pages 1026-1034 , June 2009

Article Tools

* Image Usage & Resolution